These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25122444)

  • 21. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
    Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
    Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
    Qin Y; Liu XJ; Li L; Liu XJ; Li Y; Gao RJ; Shao RG; Zhen YS
    Oncol Rep; 2014 Jul; 32(1):121-30. PubMed ID: 24807584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin.
    Jiang W; Shang B; Li L; Zhang S; Zhen Y
    Anticancer Drugs; 2016 Jan; 27(1):24-8. PubMed ID: 26457548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.
    He S; Zhao C; Tao H; Sheng W; Gao R; Liu X; Zhen Y
    Drug Deliv; 2022 Dec; 29(1):1243-1256. PubMed ID: 35416106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
    Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
    Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].
    Yang J; Chen SZ
    Yao Xue Xue Bao; 2010 Oct; 45(10):1247-53. PubMed ID: 21348302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
    Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
    Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
    Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
    Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
    Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
    Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kurbanov BM; Geilen CC; Fecker LF; Orfanos CE; Eberle J
    J Invest Dermatol; 2005 Nov; 125(5):1010-9. PubMed ID: 16297203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
    Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
    Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
    Sheng W; Gong J; Jiang M; Zhen Y
    Oncol Rep; 2017 Dec; 38(6):3507-3514. PubMed ID: 29130101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
    Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.